| Name | Title | Contact Details |
|---|
Breakthrough Behavior provides applied behavior analysis (ABA) therapy, speech therapy, and psychological testing services to children and young adults with autism and other developmental disabilities.
Solesis is an innovative provider of biomaterials solutions and services primarily focused on the medical device and advanced therapy industries.
Embecta will be the name of the independent, publicly-traded company that will hold BD`s Diabetes Care business
Relieve Pain, Restore Hope And Reimagine Your Life. Axon Therapy offers an entirely new way to resolve chronic nerve pain. Let us help you return to the life you’ve been missing, on the other side of pain.
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.